Neovasc (NASDAQ:NVCN) : Average target price received by Neovasc (NASDAQ:NVCN) is $10.87 with an expected standard deviation of $1.23. The most aggressive target on the stock is $12, whereas the most downbeat target is $10. 2 financial analysts are currently covering the stock.
Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Ladenburg Thalmann downgrades its outlook on Neovasc (NASDAQ:NVCN). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Buy. The rating by the firm was issued on May 20, 2016.
Neovasc (NASDAQ:NVCN): On Thursdays trading session , Opening price of the stock was $0.608 with an intraday high of $0.608. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.532. However, the stock managed to close at $0.5496, a loss of 7.07% for the day. On the previous day, the stock had closed at $0.5914. The total traded volume of the day was 2,222,985 shares.
The company shares have dropped -91.55% from its 1 Year high price. On Jun 25, 2015, the shares registered one year high at $7.10 and the one year low was seen on May 20, 2016. The 50-Day Moving Average price is $1.14 and the 200 Day Moving Average price is recorded at $3.11.
Neovasc Inc. is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Reducer for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products, including transcatheter heart valves. Its Tiara is a product for treating mitral valve disease. The Tiara is in preclinical/early clinical stage development to provide an invasive transcatheter device. The Tiara valve is made up of two components: the leaflets and skirt. It produces Peripatch, a biological tissue product that is manufactured from pericardium, which is the protective sac that surrounds the heart of an animal. It provides product development and specialized manufacturing services related to Peripatch tissue-based products.